Industry News — Clinical Updates

Advanced Cell Technology Treats Final Patient in Stargardt’s Macular Degeneration Phase 1 Trial

Advanced Cell Technology, Inc. (Marlborough, MA) has completed treatment of the final patient in its United Kingdom-based Phase 1 clinical trial for Stargardt’s macular degeneration (SMD).

The transplantation of its proprietary retinal pigment epithelium (RPE) cells in the final patient of 12 denotes completion of the enrollment stage of the trial. The trial is a prospective, open-label study to determine the safety and tolerability of Advanced Cell Technology’s RPE cell therapy following subretinal transplantation.

Advanced Cell Technology is working with regulatory agencies in the US and Europe to commence multi-site Phase 2 clinical trials to further examine the efficacy and safety of its RPE cell therapy in patients suffering from SMD, as well as dry AMD.

Updated September 25, 2014

Designed and built in Chicago by Webitects